UroGen Pharma (URGN) has drawn fresh attention after its latest share price move, with the stock closing at $40.70. Recent returns show a mixed pattern across the past week, month, and past 3 months.
Against that latest move, UroGen Pharma’s 1-day share price return declined 1.76%, rounding off a month that is down 7.69% on a share price basis. The stock remains tied to a year-to-date share price gain of 79.22% and a 1-year total shareholder return of 134.85%.
Scan how UroGen Pharma compares with other high momentum biotech plays using our curated list of 20 high quality undiscovered gems before you move on to your next idea.
After a sharp run over the past year but a softer recent patch, UroGen Pharma now sits in a very different spot than it did in January. Does it make more sense to step in here or wait for a cheaper entry as you weigh valuation next?
Most Popular Narrative: 32% Undervalued
On the most followed narrative, UroGen Pharma’s fair value sits at $60 against a last close of $40.70, which frames a wide valuation gap that analysts largely attribute to its bladder cancer franchise and broader urothelial pipeline.
The shift toward minimally invasive, office-based therapies (away from repeated surgeries) and demonstrated long-term durability data for ZUSDURI directly align with industry-wide transitions in care standards, supporting broader market penetration and the company's ability to command premium pricing, thus improving future net margins and profitability.
See why 15 investors see UroGen Pharma as 32% undervalued.
The fair value narrative uses a 7.56% discount rate and folds in expectations for UroGen Pharma’s urothelial cancer portfolio, including Zusduri and late-stage candidates like UGN-103 and UGN-104, to explain the gap between current market pricing and the $60 figure.
That framework rests on analyst forecasts that call for rapid revenue expansion, a shift from current operating losses toward positive margins over time, and a future P/E multiple that sits below the broader US biotech peer group, while also accounting for clinical, reimbursement, and funding risks flagged around the business.
Result: Fair Value of $60 (UNDERVALUED)
Still, the narrative around UroGen Pharma can break quickly if high operating costs keep net losses elevated or if ZUSDURI uptake slows while reimbursement hurdles linger.
Find out about the key risks to this UroGen Pharma narrative.
Next Steps
Mixed messages so far on UroGen Pharma’s value case. If you want to move quickly, review both the upside drivers and pressure points in our breakdown of 3 key rewards and 3 important warning signs.
Looking for more UroGen Pharma-sized ideas?
If you like what you see with UroGen Pharma but do not want to stop at a single ticker, the Simply Wall St Screener helps you quickly surface other focused opportunities ready for deeper research.
- Target resilient candidates that aim to keep drawdowns in check by running a filter built around 31 resilient stocks with low risk scores.
- Hunt for stronger balance sheets by scanning the list of solid balance sheet and fundamentals (25 results) and focus your time on companies with sturdier financial foundations.
- Press your advantage on pricing by scanning the 29 high quality undervalued stocks that many investors might be overlooking right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com